The Effects of Maxipost (BMS 204352) on Cerebral Hemodynamic and Headache in Healthy Volunteers and Migraine Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03887325|
Recruitment Status : Recruiting
First Posted : March 22, 2019
Last Update Posted : July 9, 2019
It is not previously investigated whether, there is a correlation between potassium channels and migraine, so it is unclear whether, this signaling pathway through potassium channels has an impact on migraine pathophysiology.
Maxipost (BMS 204352) is a vasoactive molecule that causes vasodilation via the big calcium dependent potassium (BKCa) channel signaling pathway. Maxipost decreases the blood pressure and maxipost infusion causes headache in healthy volunteers. A possible coherence between maxipost and headache/migraine in healthy volunteers and migraine patients is yet to be investigated.
The present study aims to clarify a possible coherence between maxipost and headache/migraine and it will help to shed light on the importance of potassium channels in migraine. In general, the study will contribute to a greater understanding of migraine pathogenesis and possibly lead to development of specific migraine treatment.
|Condition or disease||Intervention/treatment||Phase|
|Headache, Migraine||Drug: Maxipost Drug: Saline||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||To Investigate the Headache Induction and the Cerebral Hemodynamic Changes After Infusion of Maxipost in Healthy Volunteers and Migraine Patients|
|Actual Study Start Date :||April 1, 2019|
|Estimated Primary Completion Date :||June 30, 2020|
|Estimated Study Completion Date :||June 30, 2021|
|Active Comparator: Maxipost||
To investigate the role of maxipost on cerebral hemodynamic and headache in healthy volunteers and migraine patients
|Placebo Comparator: Saline||
To investigate the role of saline on cerebral hemodynamic and headache in healthy volunteers and migraine patients
- Change in cerebral hemodynamic [ Time Frame: Before (-10 minutes) and after infusion (+2 hours) of maxipost compared with before and after infusion of saline ]Change on velocity of media cerebri artery. Change on velocity will be measured with centimeter (cm) /second.
- Occurrence and change of headache [ Time Frame: Before (-10 minutes) and after infusion (+12 hours) of maxipost compared with before and after infusion of saline ]Occurrence of headache measured by numerical rating scale (NRS)
- Occurrence and change of migraine attack [ Time Frame: Before (-10 minutes) and after infusion (+12 hours) of maxipost compared with before and after infusion of saline ]Occurrence and of migraine according to international criteria
- Change of diameter of the artery [ Time Frame: Before (-10 minutes) and after infusion (+2 hours) of maxipost compared with before and after infusion of saline ]Change of diameter of superficial temporal artery and radial artery. The diameter will be measured by centimeter (cm)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03887325
|Contact: Mohammad A Al-Karagholiemail@example.com|
|Danish headache center||Recruiting|
|Glostrup, Copenhagen, Denmark, 2600|
|Contact: Mohammad A Al-Karagholi 31191647 firstname.lastname@example.org|
|Principal Investigator:||Messoud A Ashina||Danish Headache Center|